The price of CASI is predicted to go up 17.56%, based on the high correlation periods with SLNH. The similarity of these two price pattern on the periods is 95.09%.

CASI

SLNH

Up: 17.56%Similarity: 95.09%

CASI Revenue Forecast

CASI EPS Forecast

CASI FAQs

What is bull’s view on CASI?

CASI Pharmaceuticals (CASI) is currently trading under pressure due to mixed financial results and ongoing challenges, such as the Evomela® license termination dispute. Despite a recent EPS improvement (-$0.52 vs. -$0.63 expected in Q2 2024), revenue missed estimates, and the $200M mixed securities shelf filing signals potential dilution risks. The stock lacks clear bullish momentum unless significant positive catalysts emerge.

What is bear's view on CASI?

CASI stock closed at $2.475 on January 31, 2025, with a slight decline of 0.80%. The bearish view stems from its weak financial performance, including a Q3 2024 EPS of -$0.55 despite improvement from the prior year, and ongoing challenges like the Evomela® license termination dispute. Additionally, the recent $200M mixed securities shelf filing signals potential dilution, further pressuring the stock price.